Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
Ajouter des filtres








Gamme d'année
1.
Int. j. cardiovasc. sci. (Impr.) ; 34(2): 211-222, Mar.-Apr. 2021. tab, graf
Article Dans Anglais | LILACS | ID: biblio-1154542

Résumé

Abstract Chloroquine (CQ) and Hydroxychloroquine (HCQ) are antimalarial drugs, with anti-inflammatory properties that justify their use in the treatment of systemic lupus erythematosus and rheumatic diseases. A pandemic caused by the new coronavirus led the entire world's scientific community to look for drugs already available on the market, capable of exercising beneficial actions in the fight against the disease. Preliminary studies in patients, as well as in vitro studies, suggested possible therapeutic effects associated with the use of HCQ and CQ in the treatment of COVID-19. Despite controversies over the effects of these drugs in combating the "cytokine storm" associated with COVID and the dismal of results in different clinical trials in Brazil, their use has been encouraged and several ongoing investigative studies are underway. In addition to the possible beneficial effects on the prognosis of patients with SARS-CoV-2, such drugs include varied effects on the cardiovascular system, ranging from positive developments related to their vasodilator properties to potential negative effects, such as cardiotoxicity. This work presents the main effects exerted by these drugs on the cardiovascular system, in order to contribute to a scientific discussion about the repurposing of these drugs in the context of COVID-19.


Sujets)
Chloroquine/toxicité , Azithromycine/usage thérapeutique , COVID-19/traitement médicamenteux , Chloroquine/effets indésirables , Chloroquine/usage thérapeutique , Azithromycine/effets indésirables , Azithromycine/toxicité , Interactions médicamenteuses
2.
Rev. saúde pública (Online) ; 54: 68, 2020. graf
Article Dans Anglais | BBO, LILACS | ID: biblio-1127241

Résumé

ABSTRACT Chloroquine (CQ) and its analog hydroxychloroquine (HCQ) were recently included in several clinical trials as potential prophylactic and therapeutic options for SARS-COV-2 infection/covid-19. However, drug effectiveness in preventing, treating, or slowing the progression of the disease is still unknown. Despite some initial promising in vitro results, rigorous pre-clinical animal studies and randomized clinical trials have not been performed yet. On the other hand, while the potential effectiveness of CQ/HCQ is, at best, hypothetical, their side effects are factual and most worrisome, particularly when considering vulnerable groups of patients being treated with these drugs. in this comment, we briefly explain the possible mechanisms of action of CQ/HCQ for treating other diseases, possible actions against covid-19, and their potent side effects, in order to reinforce the necessity of evaluating the benefit-risk balance when widely prescribing these drugs for SARS-COV-2 infection/covid-19. We conclude by strongly recommending against their indiscriminate use.


Sujets)
Humains , Pneumopathie virale/traitement médicamenteux , Chloroquine/pharmacologie , Infections à coronavirus/traitement médicamenteux , Betacoronavirus/effets des médicaments et des substances chimiques , Hydroxychloroquine/pharmacologie , Antipaludiques/pharmacologie , Chloroquine/effets indésirables , Chloroquine/pharmacocinétique , Appréciation des risques , Pandémies , Contre-indications aux médicaments , SARS-CoV-2 , COVID-19 , Hydroxychloroquine/effets indésirables , Hydroxychloroquine/pharmacocinétique , Antipaludiques/effets indésirables , Antipaludiques/pharmacocinétique
SÉLECTION CITATIONS
Détails de la recherche